By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the burning questions is whether to select the most recent third-generation agent or to combine a first- or second-generation TKI with chemotherapy or antiangiogenic agents and…